Epithelioid sarcoma

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Section editor
Elizabethdavis2.jpg
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN

Social-twitter-icon.png ejdavis25

Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page
1 variants on this page


All lines of therapy

Tazemetostat monotherapy

Regimen

FDA-recommended dose
Study Years of enrollment Evidence
Gounder et al. 2020 (EZH-202) 2015-2017 Phase 2 (RT)

Biomarker eligiblity criteria

One or both of the following:

  • Loss of INI1 expression by IHC
  • Biallelic SMARCB1 alterations

Targeted therapy

28-day cycles

References

  1. EZH-202: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. Epub 2020 Oct 6. link to original article contains protocol PubMed NCT02601950